Patrick Mollon

934 total citations
33 papers, 740 citations indexed

About

Patrick Mollon is a scholar working on Economics and Econometrics, Rheumatology and Urology. According to data from OpenAlex, Patrick Mollon has authored 33 papers receiving a total of 740 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Economics and Econometrics, 10 papers in Rheumatology and 8 papers in Urology. Recurrent topics in Patrick Mollon's work include Health Systems, Economic Evaluations, Quality of Life (11 papers), Pelvic floor disorders treatments (8 papers) and Urinary Bladder and Prostate Research (8 papers). Patrick Mollon is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (11 papers), Pelvic floor disorders treatments (8 papers) and Urinary Bladder and Prostate Research (8 papers). Patrick Mollon collaborates with scholars based in United States, United Kingdom and Switzerland. Patrick Mollon's co-authors include Raymond C. Rosen, Lalitha P. Aiyer, Carol L. Link, John B. McKinlay, Kevin T. McVary, Varant Kupelian, Steven A. Kaplan, Susan A. Hall, Nihad Tamimi and L. Puig and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and Annals of Oncology.

In The Last Decade

Patrick Mollon

32 papers receiving 728 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patrick Mollon United States 13 391 249 149 148 142 33 740
Ester Illiano Italy 17 293 0.7× 347 1.4× 108 0.7× 73 0.5× 143 1.0× 83 805
Jean-Michel Joubert France 12 48 0.1× 256 1.0× 31 0.2× 24 0.2× 47 0.3× 42 472
Ira Greifer United States 18 60 0.2× 66 0.3× 40 0.3× 80 0.5× 223 1.6× 51 1.1k
Mitchell Edson United States 13 96 0.2× 70 0.3× 60 0.4× 45 0.3× 142 1.0× 37 636
John E. Lewy United States 17 54 0.1× 32 0.1× 70 0.5× 37 0.3× 195 1.4× 44 735
David S. Lirenman Canada 14 58 0.1× 123 0.5× 10 0.1× 39 0.3× 122 0.9× 32 645
Sepehr Salem Iran 12 152 0.4× 59 0.2× 67 0.4× 50 0.3× 134 0.9× 20 544
Seung Hyun Jeon South Korea 16 141 0.4× 129 0.5× 23 0.2× 66 0.4× 359 2.5× 75 690
Kimberly Siu United States 15 123 0.3× 58 0.2× 11 0.1× 84 0.6× 16 0.1× 26 761
Kay Latta Germany 17 21 0.1× 49 0.2× 30 0.2× 68 0.5× 346 2.4× 51 1.0k

Countries citing papers authored by Patrick Mollon

Since Specialization
Citations

This map shows the geographic impact of Patrick Mollon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Mollon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Mollon more than expected).

Fields of papers citing papers by Patrick Mollon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Mollon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Mollon. The network helps show where Patrick Mollon may publish in the future.

Co-authorship network of co-authors of Patrick Mollon

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Mollon. A scholar is included among the top collaborators of Patrick Mollon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Mollon. Patrick Mollon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Freemantle, Nick, Patrick Mollon, Tim Meyer, et al.. (2022). Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial. European Journal of Cancer. 168. 91–98. 7 indexed citations
2.
3.
Venerito, Marino, Jörg Trojan, Patrick Mollon, et al.. (2021). Comparative efficacy of cabozantinib and ramucirumab after sorafenib for patients with advanced hepatocellular carcinoma and AFP ≥ 400 ng/ml. Zeitschrift für Gastroenterologie. 4 indexed citations
4.
Kelley, Robin Kate, Patrick Mollon, Jean‐Frédéric Blanc, et al.. (2020). Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma. Advances in Therapy. 37(6). 2678–2695. 45 indexed citations
5.
Strasser, Simone I., Ghassan K. Abou‐Alfa, Patrick Mollon, et al.. (2019). Quality-adjusted life-years accrued with cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial. UCL Discovery (University College London).
6.
Strober, Bruce, Alice B. Gottlieb, Bintu Sherif, et al.. (2017). Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. Journal of the American Academy of Dermatology. 76(4). 655–661. 19 indexed citations
7.
8.
Gwaltney, Chad, et al.. (2016). Symptoms and Functional Limitations in the First Year Following a Myocardial Infarction: A Qualitative Study. Patient. 10(2). 225–235. 9 indexed citations
9.
Graham, Christopher N., et al.. (2015). A New Cost-Effectiveness Framework For Modeling Psoriasis Treatments. Value in Health. 18(3). A20–A20. 3 indexed citations
10.
Graham, Christopher N., et al.. (2015). Estimation of Indirect (Work-Related Productivity) Costs Associated With Moderate-To-Severe Plaque Psoriasis In Germany. Value in Health. 18(7). A419–A419. 3 indexed citations
11.
González, Juan Marcos, Christine Poulos, & Patrick Mollon. (2014). Understanding Medication Adherence Using Stated-Preference Data. Value in Health. 17(7). A492–A493. 1 indexed citations
12.
Jain, Minal, et al.. (2014). The Economic Impact Of Cardiovascular Events In Patients Post Myocardial Infarction: Uk Health Care Perspective. Value in Health. 17(7). A483–A484. 2 indexed citations
13.
Friedman, Howard, Patrick Mollon, Jean Lian, & Prakash Navaratnam. (2013). Clinical Outcomes, Health Resource Use, and Cost in Patients with Early versus Late Dual or Triple Anti-Platelet Treatment for Acute Coronary Syndrome. American Journal of Cardiovascular Drugs. 13(4). 273–283. 4 indexed citations
14.
Chancellor, J, et al.. (2010). A Microsimulation of the Cost-effectiveness of Maraviroc for Antiretroviral Treatment-Experienced HIV-Infected Individuals. HIV Clinical Trials. 11(2). 80–99. 15 indexed citations
15.
Kupelian, Varant, Kevin T. McVary, Steven A. Kaplan, et al.. (2009). Association of Lower Urinary Tract Symptoms and the Metabolic Syndrome: Results From the Boston Area Community Health Survey. The Journal of Urology. 182(2). 616–625. 159 indexed citations
16.
Kupelian, Varant, Kevin T. McVary, Michael J. Barry, et al.. (2009). Association of C-reactive Protein and Lower Urinary Tract Symptoms in Men and Women: Results From Boston Area Community Health Survey. Urology. 73(5). 950–957. 64 indexed citations
17.
Hall, Susan A., Carol L. Link, Sharon L. Tennstedt, et al.. (2009). Urological symptom clusters and health‐related quality‐of‐life: results from the Boston Area Community Health Survey. British Journal of Urology. 103(11). 1502–1508. 12 indexed citations
18.
Kelly, Steven, et al.. (2008). Antiretroviral effects on HIV‐1 RNA, CD4 cell count and progression to AIDS or death: a meta‐regression analysis. HIV Medicine. 9(10). 849–857. 11 indexed citations
19.
Rosen, Raymond C., Karin S. Coyne, David B. Henry, et al.. (2008). Beyond the cluster: methodological and clinical implications in the Boston Area Community Health survey and EPIC studies. British Journal of Urology. 101(10). 1274–1278. 12 indexed citations
20.
Shearer, Arran, Paul Scuffham, & Patrick Mollon. (2004). The cost of coronary artery disease in the UK. British Journal of Cardiology. 11(3). 218–223. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ester Illiano Breakdown of academic impact, for papers by Jean-Michel Joubert Breakdown of academic impact, for papers by Ira Greifer Breakdown of academic impact, for papers by Mitchell Edson Breakdown of academic impact, for papers by John E. Lewy Breakdown of academic impact, for papers by David S. Lirenman Breakdown of academic impact, for papers by Sepehr Salem Breakdown of academic impact, for papers by Seung Hyun Jeon Breakdown of academic impact, for papers by Kimberly Siu Breakdown of academic impact, for papers by Kay Latta
Rankless by CCL
2026